Considerations In Design And Development Of Novel Combination Drug-Delivery Devices

If you're starting a novel drug delivery device program, the scoping phase will determine more about your eventual success than almost anything that comes after it. Not platform technology, not a variant, but something genuinely new. The stakes around getting the problem definition right are high, and most teams underestimate them.

Phase 0, or project initiation, is where clinical needs get translated into a formal project structure. Done well, it prevents scope creep and keeps regulatory and market realities in view from day one. That means drafting a problem statement that honestly captures the pain points for patients, caregivers, and clinicians, not a vague aspiration. It means identifying your unique selling point early enough that it actually shapes development decisions. And it means doing a genuine opportunity and risk assessment, using tools like SWOT or FMEA, before momentum makes course correction expensive.

Regulatory classification, whether FDA Class I, II, or III, and the patent landscape both need to be scoped at this stage too. These aren't downstream concerns. Access the full series to build a scoping process that holds up under real development pressure.